Develops immunotherapies for cancer treatment, focusing on T-cell therapies.
Instil Bio, Inc., a dynamic clinical-stage biopharmaceutical company, is dedicated to pioneering innovative therapies for cancer patients. Specializing in cell therapy, Instil Bio focuses on developing autologous tumor infiltrating lymphocyte (TIL) treatments. The company's robust pipeline includes promising TIL product candidates such as ITIL-168, targeting indications such as melanoma, cutaneous squamous cell carcinoma, non-small cell lung cancer, head and neck squamous cell carcinoma, and cervical cancer. Additionally, ITIL-306 aims to target folate receptor alpha (FOLR1), addressing conditions including gynecological cancers, non-small cell lung cancer, renal cancer, and others.
In addition to its groundbreaking therapies, Instil Bio collaborates extensively within the biopharmaceutical industry to advance its innovative treatments. The company was founded in 2018 and is headquartered in Dallas, Texas, strategically positioning itself at the forefront of cancer research and development. With a steadfast commitment to improving patient outcomes through cutting-edge therapies, Instil Bio continues to expand its capabilities and pursue new avenues in oncology treatment.